At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Metastatic Renal Cell Carcinoma
In Brief
A Phase 1 clinical trial evaluating Clostridium butyricum CBM 588 Probiotic Strain, Ipilimumab, and 1 other intervention for Advanced Renal Cell Carcinoma and 5 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This phase I trial studies how well CBM588 works when given together with nivolumab and ipilimumab in treating patients with kidney cancer that is stage IV or has spread to other places in the body (advanced). CBM588 is a probiotic that may help to increase the effect of immunotherapy. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CBM588, nivolumab, and ipilimumab may work better in treating patients with kidney cancer.
Study Details
Timeline
Interventions
Given PO
Given IV
Given IV